Skip to content

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Aug 22, 2000
SAN DIEGO, Aug. 22 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the issuance of United States Patent Number 6,107,324 entitled "Non-Endogenous Constitutively Activated Human Serotonin Receptors and Small Molecule Modulators Thereof." This is the first patent issued to Arena since its inception in April of...
Aug 10, 2000
SAN DIEGO, Aug. 10 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the underwriters led by ING Barings LLC, Prudential Securities Incorporated, and SG Cowen Securities Corporation, have exercised in full their over-allotment option in connection with Arena's initial public offering, and purchased an addi...
Aug 1, 2000
THE WOODLANDS, Texas, Aug. 1 /PRNewswire/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - news) today announced the formalization of a joint research collaboration with Arena Pharmaceuticals (Nasdaq: ...
Jul 28, 2000
SAN DIEGO, July 28 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that its initial public offering of 6,000,000 shares of its common stock was priced at $18 per share, above the initial filing range of $15-$17 per share. All of the shares are being sold by Arena. The shares will be offered through an underw...
Jul 28, 2000
NEW YORK, July 28 (Reuters) - The initial public offering market has regained the pizazz that made it famous during its heyday last year -- at least for now.While the technology-rich Nasdaq composite index (^IXIC - news...
Jul 28, 2000
July 28, 2000--Arena Pharmaceuticals, Inc. (Nasdaq:ARNA - news) was admitted to the Nasdaq National Market System following its initial public offering of 6 million shares at $18 per share. The company's stock trades under the ticker symbol ARNA. Company address: 6...
Jul 27, 2000
NEW YORK, July 27 (Reuters) - Arena Pharmaceuticals Inc. (Nasdaq:ARNA - news) sold 6 million shares at $18 per share, above the estimated price range, in its initial public offering on Thursday, according to the...
Jul 25, 2000
WASHINGTON, July 25 (Reuters) - Arena Pharmaceuticals Inc. on Tuesday raised its initial public offering (IPO) to 6 million shares of common stock from 5 million shares.The company, which says it has developed technology that identifies drug candidates more efficiently that traditional techniques,...
Jun 22, 2000
WASHINGTON, June 22 (Reuters) - Arena Pharmaceuticals Inc., which says it has found a new way of finding new drug candidates more efficiently, on Thursday said it will offer five million shares in a projected price range of $15-$17 per share when it goes public.It expects to raise about $73...
Apr 17, 2000
INDIANAPOLIS, April 17 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Arena Pharmaceuticals, Inc., announced today that they have entered into an agreement to develop a number of orphan G-protein coupled receptors (GPCRs) as drug screening targets, utilizing Arena's proprietary CART™...
Jan 31, 2000
SAN DIEGO, Jan. 31 /PRNewswire/ -- Arena Pharmaceuticals, Inc. ("Arena"), a privately held biopharmaceutical company, today announced that Arena and Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan ("Fujisawa") have entered into a collaboration involving Arena's proprietary CART™ Technology...
Jan 19, 2000
SAN DIEGO, Jan. 19 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Arena™), a privately-held biotechnology company, announced today that it was awarded a one-year, $106,000 Small Business Innovation Research (SBIR) grant from the National Institute of Mental Health (NIMH). The Company will ...
Sep 15, 1999
SAN DIEGO, Sept. 15 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Arena Pharmaceuticals, Inc. ("Arena"), a privately held biopharmaceutical company, today announced a collaboration involving the application of Arena's constitutive activation technology to three Neurocrine orphan G protein-coupled recepto...
Apr 17, 1999
SAN DIEGO, May 17 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Arena™), a privately-held biotechnology company, announced the successful completion of a Phase I clinical investigation of the safety and pharmacokinetics of T-82 in healthy, elderly volunteers. This was a first-in-man study ...
Feb 22, 1999
SAN DIEGO, Feb. 22 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Arena™), a privately-held biotechnology company, has announced the successful completion of a private offering through the sale of its Series D Preferred Stock. Arena had intended to raise $10 Million through this offer...
= add release to Briefcase